Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/2/2025

Efficacy and Safety of Placental-Derived Products for Wound Healing

Introduction to Placental-Derived Products

  • The International Working Group on the Diabetic Foot (IWGDF) provides a conditional recommendation with low-quality evidence for using placental-derived products as adjunct therapy for diabetic foot ulcers when standard care alone has failed 1

Clinical Outcomes

  • Studies suggest improved absolute wound healing at timepoints between 4-20 weeks compared to standard care 1, 2
  • Reduced time to healing has been reported in studies, though many were assessed as having high risk of bias 1
  • Percentage area reduction was improved in five studies, though two had high risk of bias 1
  • No significant difference in new infection rates was reported 1
  • No evidence of impact on amputation rates was found 1

Cost Considerations

  • The cost of intervention per healed ulcer was over $2,000 for dehydrated human amniotic membrane and over $3,000 for dehydrated umbilical cord products 1
  • Formal cost-effectiveness data was only published in one post-hoc analysis of a study judged at high risk of bias 1

Specific Types of Placental Products

  • A well-designed single-blind RCT showed higher incidence of ulcer closure after 12 weeks with weekly application of cryopreserved amniotic membrane allograft compared to standard care 3
  • A three-arm RCT comparing bioengineered skin substitute, amniotic membrane product, and collagen-alginate dressing found highest healing rates within 12 weeks for the amniotic membrane product 3

Safety Considerations

  • Studies on umbilical cord milking found no difference in mortality compared to immediate cord clamping 4, 5
  • No evidence of adverse effects in preterm infants or their mothers after umbilical cord milking compared with immediate cord clamping 6

Clinical Application Guidance

  • Consider placental-derived products only after standard care has failed to reduce ulcer size 1, 2
  • Most suitable for diabetic foot ulcers without significant peripheral arterial disease 1
  • Not recommended for routine use in all wound types due to limited evidence 1

Knowledge Gaps and Future Research Needs

  • Long-term outcomes including quality of life and function are not well studied 1
  • Formal cost-effectiveness analyses are needed 1, 3
  • Optimal patient selection criteria are not established 3